Abstract:Objective: To investigate risk factors for locoregional recurrence (LRR) of pathologic stage IIIA-N2 non-small cell lung cancer (pIIIA-N2 NSCLC) and construct a prediction model for risk score to determine a patient's risk for LRR and guide the selection of postoperative radiotherapy (PORT). Methods: The clinical, pathologic, and biological data of 107 patients with pIIIA-N2 NSCLC treated at Fujian Provincial Hospital between May 2012 and December 2018 were analyzed retrospectively. None of the patients had positive surgical margins, and none received preoperative treatment or PORT. The Kaplan-Meier method was used for a univariate analysis of possible factors for locoregional recurrence-free survival (LRFS). The Cox regression model was used in a multivariate analysis to identify independent risk factors for LRFS, which were used to construct a prediction model for risk score. The concordance index was calculated to evaluate discrimination. Results: The median follow-up time was 31.2 months. During the follow-up, 69 (64.5%) patients had LRR and/or distant metastasis (DM). Among them, 46 (43%) patients had LRR (with or without DM), and 56 (52.3%) patients had DM (with or without LRR). The 1-year LRFS, distant metastasis-free survival, disease-free survival, and overall survival rates were 78.2%, 78%, 69.8%, and 90.2%, respectively; the 3-year rates were 50.6%, 41.2%, 31.2%, and 66.3%, respectively. Multivariate analysis showed that surgical approach (hazard ratio [HR], 0.348; 95% confidence interval [CI], 0.175-0.693; P = 0.003), metastatic N2 lymph node ratio (HR, 3.597; 95% CI, 1.832-7.062; P = 0.000), epidermal growth factor receptor status (HR, 3.666; 95% CI, 1.724-7.797; P = 0.001), and lymphocyte-to-monocyte ratio (HR, 2.364; 95% CI, 1.221-4.574; P = 0.011) were independent risk factors for LRFS. These independent risk factors were used to construct a prediction model for risk score and stratify patients into the low-risk group (risk score: 0-2), medium-risk group (risk score: 3-5), and high-risk group (risk score: 6-13). The 1-year LRFS rates of these groups were 91.9%, 85.3%, and 54.6%, respectively; the 3-year LRFS rates were 71.4%, 57.3%, and 13.6%, respectively. These between-group differences were significant (P = 0.000). The prediction model showed good discrimination (concordance index = 0.747, 95% CI, 0.678-0.816). Conclusion: Our prediction model for risk score based on characteristics of pIIIA-N2 NSCLC patients may help clinicians predict a patient's risk for LRR. Further investigations of PORT with patients in different risk groups are warranted.

A Clinicopathologic Prediction Model for Postoperative Recurrence in Stage Ia Non-Small Cell Lung Cancer.

Prediction of Recurrence of Early Gastric Cancer after Curative Resection

Establishment and validation of a nomogram model for predicting postoperative recurrence-free survival in stage IA3 lung adenocarcinoma: a retrospective cohort study

Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma

Establishment and validation of a clinicopathological prediction model for postoperative recurrence of stage IA lung adenocarcinoma

A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection

A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer

A Nomogram Based on Consolidation Tumor Ratio Combined with Solid or Micropapillary Patterns for Postoperative Recurrence in Pathological Stage IA Lung Adenocarcinoma.

Clinical, Imaging, and Pathological-Molecular Characteristics Associated with Stage IA Invasive Lung Adenocarcinoma Recurrence After Sub-lobar Resection

A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer

Patterns and Risks of Postoperative Recurrence in Completely Resected EGFR-mutant Non-Small Cell Lung Cancer: Prognostic Significance of Routine Immunohistochemical Markers

A Clinical Risk Model for Assessing the Survival of Patients with Stage IA-IIA Non-Small Cell Lung Cancer after Surgery.

The Genomic and Transcriptomic Characteristics of Early Recurrence Patients in Stage IA Non-Small Cell Lung Cancer.

Prognostic Factors in Curatively Resected Pathological Stage I Lung Adenocarcinoma

Risk Factors for Recurrence after Complete Resection of Pathological Stage N2 Non-Small Cell Lung Cancer

Application of a Comprehensive Model Based on CT Radiomics and Clinical Features for Postoperative Recurrence Risk Prediction in Non-small Cell Lung Cancer

[Analyses of Risk Factors for Postoperative Recurrence after Curative Resection of Stage III A-N2 Non-Small Cell Lung Cancer].

Risk Factors of Recurrence for Resected T1aN0M0 Invasive Lung Adenocarcinoma: a Clinicopathologic Study of 177 Patients

Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients with Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.

[Analysis of Recurrence Patterns after Curative Resection of Stage IIIA-N2 Non-Small Cell Lung Cancer].